Results

Total Results: 1,643 records

Showing results for "factor".

21. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/musculoskeletal-complaints-tests-children_research-protocol.pdf
    September 29, 2010 - Evidence-based Practice Center Systematic Review Protocol Project Title: Antinuclear Antibody, Rheumatoid Factor … or limb or joint swelling may use serological tests such as antinuclear antibody (ANA), rheumatoid factor … The rheumatoid factor (RF) test is the most commonly used serological test to determine the presence … Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: A review. … • Rheumatoid factor test (RF): The measure of serum level of rheumatoid factor antibody which is

22. Treatment of Osteoarthritis of the Knee: An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/osteoarthritis-knee-update_research-protocol.pdf
    June 15, 2016 - natural joint lubricant, hyaluronic acid (HA), experimental use of biologic agents (anti-nerve growth factor … antibodies or anti-tumor necrosis factor antibodies, which are used to treat rheumatoid arthritis), … FDA- CMS National Coverage Determination: Plasma AAOS: unable to recommend for or against growth factor … '/exp OR 'nerve growth factor' OR (('fibroblast' OR 'fibroblast'/exp OR fibroblast) AND ('growth' OR … '/exp OR 'nerve growth factor' OR ('fibroblast' OR 'fibroblast'/exp OR fibroblast AND ('growth' OR '

23. Executive Summary_Systematic Review: Mental Health and Occupational Stress in the Emergency Medical Services and 911 Workforces (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ems-911-workforce-mental-health-executive-summary.pdf
    February 01, 2025 - 1: Associations between modifying factors and all outcomes among telecommunicators Level Modifying Factor … Numbers in parentheses refer to numbers of studies that evaluated the modifying factor (row) for the … between modifying factors and all outcomes among Emergency Medical Services clinicians Level Modifying Factor … No psychological help . . ↑ (1) . . . . . . 11 Level Modifying Factor Depression … Numbers in parentheses refer to numbers of studies that evaluated the modifying factor (row) for the

24. S116 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s116.pdf
    October 01, 2007 - This factor will be a valid IV if: (1) physicians vary in their preference for using the 2 different … The reported prevalence difference (PD) is the prev- alence of the risk factor among patients started … on an atypical APM minus the prevalence of the risk factor among patients started on a conventional … The reported PD for the IV is the prevalence of the risk factor among patients of physicians who have … †Prevalence of risk factor among atypical users minus prevalence of risk factor among conventional users

25. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0319_06-17-2009.pdf
    January 01, 2009 - fibrinogen, leukocyte count, prothrombin time, partial thrombin time, interleukin 6, and tumor necrosis factor … fibrinogen, leukocyte count, prothrombin time, partial thrombin time, interleukin 6, and tumor necrosis factor

26. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-biopsy-executive.pdf
    December 01, 2009 - intended to evaluate the accuracy of different methods of performing breast biopsy and to explore what factor … factors on accuracy and harms Strength of evidence Impact on Impact on supporting the Category Factor … improves Insufficient data Insufficient experience with experience Insufficient data for any other factor … category Factor Level of evidence factor on accuracy Patient characteristics Patient age Insufficient … on Factor category Factor Level of evidence harms Patient characteristics Patient age Insufficient

27. Untitled (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/thromboembolism-update_research-protocol.pdf
    February 17, 2016 - There were few studies evaluating the new factor Xa inhibitors. … or treatment durations of the same thromboprophylaxis interventions (low molecular weight heparin, factor … All KQ o   Injectable unfractionated heparin KQ 1, 4 (in combination), 5, 6 o   Injectable or oral factor …  for  postthrombotic   syndrome  and  proximal  DVTs  are  believed  to  be  a  higher  risk  factor … 1) comparisons of classes of thromboprophylaxis interventions (e.g., low molecular weight heparin, factor

28. 04-E029-1 Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_executive.pdf
    December 01, 2011 - Behavioral indications No cohort used this factor. … Gleason score No cohort used this factor. … Behavioral indications No cohort explicitly used this factor. … Availability of technology No study addressed this factor. … Small area variation No study addressed this factor.

29. Data Points 15: Breast Cancer Diagnostic Workup: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-prognostic-tests_research.pdf
    August 22, 2012 - Data Points 15: Breast Cancer Diagnostic Workup: Prognostic factor testing among older women with ductal … situ and early invasive breast cancer Breast Cancer Diagnostic Workup Data Points # 15 Prognostic factor … Current guidelines do not recommend routine testing for human epidermal growth factor receptor 2 (HER2 … Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast … ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor-2.

30. Musculoskeletal-Complaints-Tests-Children Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_executive.pdf
    March 01, 2012 - 1 Comparative Effectiveness Review Number 50 Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated … Frequency of antinuclear antibodies and rheumatoid factor in healthy Turkish children. … Rheumatoid factor in children with lupus erythematosus. A serologic study. … Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. … factor in juvenile chronic arthritis.

31. Quantitative Synthesis Chapter 3. Choice of Statistical Model for Combining Studies (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-3.pdf
    February 01, 2018 - For example, recommend against selecting fixed effects model because P>0.1 ► Such approaches do not factor … large effect sizes, or more frequent outcomes (5-10%), the Mantel-Haenszel method (without correction factor … consider the Peto method, the Mantel-Haenszel method, or logistic regression without correction factor … method, the Mantel- Haenszel method, or a logistic regression approach, without adding a correction factor

32. Topic Coming Back CER 28 DMARDs in Children with JIA NSD _SJ Clean (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_overview.pdf
    March 27, 2014 - g Categories of JIA include: • Systemic arthritis • Oligoarthritis • Rheumatoid-factor positive ( … RF+) polyarthritis • Rheumatoid-factor negative (RF-) polyarthritis • Enthesitis-related arthritis

33. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_executive.pdf
    September 01, 2011 - Comparative Effectiveness Review Number 28 Effective Health Care 2 • Rheumatoid-factor positive … • Rheumatoid-factor negative (RF-) polyarthritis: Affects five or more joints during the first 6 months … (FDA) recently placed a box warning on the entire class of biologic DMARDs targeting tumor necrosis factor … (g) Categories of JIA include: • Systemic arthritis • Oligoarthritis • Rheumatoid-factor positive … (RF+) Polyarthritis • Rheumatoid-factor negative (RF-) polyarthritis • Enthesitis-related arthritis

34. Quantitative Synthesis: Chapter 4. Quantifying, Testing, and Exploring Statistical Heterogeneity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-quantitative-synthesis-chapter-4.pdf
    July 01, 2019 - meta-regression is also an option, and requires consideration of these factors as well (e.g., ≥10 studies per factor … Subgroup analysis • Subgroup analysis is a form of meta-regression with a categorical study-level factor … It is recommended to incorporate the subgroup factor into a meta-regression framework.20 − This enables … under consideration of low power associated with limited studies (i.e., <10 studies per study- level factor

35. Arthritis-Psoriatric Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
    April 01, 2012 - Effective Health Care infliximab) are also classified as antitumor necrosis factor (anti-TNF) drugs … component score; SF-36 = Medical Outcomes Study Short Form 36; SSZ = sulfasalazine; TNF = tumor necrosis factor … cohort studies with low strength of evidence indicated that the combination of an anti-tumor necrosis factor … Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results … Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous

36. Observed Association Between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-seniors-pneumonia_research.pdf
    May 01, 2008 - One major etiologic factor for pneumonia in the elderly is aspiration of oropharyngeal contents [3,4 … We then examined each potential confounding factor individually using a change-in-estimate criterion … In particular, we individually added each potential confounding factor to the minimally adjusted model … If any factor changed the OR of interest by ten percent or more, we considered it to be a confounding … factor and retained it in the “change-in-estimate” adjusted model.

37. Disposition of Comments Report for Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_disposition-comments.pdf
    March 07, 2012 - Disposition of Comments Report for Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated … Research Review Disposition of Comments Report Research Review Title: Antinuclear Antibody, Rheumatoid Factor … Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal … Similarly, I am not sure that the authors are familiar with modern tests for rheumatoid factor.

38. Disposition of Comments for Venous Thromboembolism Prophylaxis in Orthopedic Surgery (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_disposition-comments.pdf
    March 01, 2012 - I would recommend NOT using FXI as the abbreviation for Factor Xa inhbitors are there are indeed Factor … Rivaroxaban binds to factor Xa in the prothrombinase complex, clot-bound factor Xa, and free factor … Effect of BAY 59-7939–a novel, oral, direct factor Xa inhibitor–on clot- bound factor Xa activity in … Compliance for the mechanical modalities remains a factor. … Factor Xa Inhibitors, rivaroxaban and apixaban.

39. Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/musculoskeletal-complaints-tests-children/research

40. Computerized Definitions Showed High Positive Predictive Values for Identifying Reasons for Hospitalizations in a Medicaid Population with Rheumatoid Arthritis (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-hospitalizations_research.pdf
    October 01, 2008 - for post marketing studies of medication safety and we are evaluating the safety of tumor necrosis factor … bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor … Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor … Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go … opportunistic infections and other serious potential adverse events associated with tumor necrosis factor